(Q37608276)

21 August 2017

1 reference

title

New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance (English)

1 reference

21 August 2017

Maria Teresa Fera

1

1 reference

PubMed ID

19803707

21 August 2017

Erminia La Camera

series ordinal

2

1 reference

PubMed ID

19803707

21 August 2017

Angelina De Sarro

series ordinal

3

1 reference

21 August 2017

1 October 2009

1 reference

Expert Review of Anti-infective Therapy

21 August 2017

1 reference

21 August 2017

7

1 reference

21 August 2017

8

1 reference

21 August 2017

981-998

1 reference

Infections due to emerging and uncommon medically important fungal pathogens

21 August 2017

1 reference

Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

21 January 2018

1 reference

Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins

21 January 2018

1 reference

Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates

21 January 2018

1 reference

New and emerging treatments for fungal infections

21 January 2018

1 reference

21 January 2018

1 reference

Update on azole antifungals

21 January 2018

1 reference

Current options in antifungal pharmacotherapy.

21 January 2018

1 reference

Molecular aspects of azole antifungal action and resistance

21 January 2018

1 reference

An update on antifungal targets and mechanisms of resistance in Candida albicans

21 January 2018

1 reference

A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity

21 January 2018

1 reference

Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species

21 January 2018

1 reference

Ca2+ binding to the first epidermal growth factor module of coagulation factor VIIa is important for cofactor interaction and proteolytic function

21 January 2018

1 reference

Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding.

21 January 2018

1 reference

A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).

21 January 2018

1 reference

Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.

21 January 2018

1 reference

Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole

21 January 2018

1 reference

A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus

21 January 2018

1 reference

Comparison of posaconazole and voriconazole in vitro killing against Candida krusei

21 January 2018

1 reference

Evaluation of voriconazole pharmacodynamics using time-kill methodology

21 January 2018

1 reference

In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species

21 January 2018

1 reference

In vitro activities of fluconazole and voriconazole against clinical isolates of Candida spp. determined by disk diffusion testing in Turin, Italy.

21 January 2018

1 reference

In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

21 January 2018

1 reference

A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.

21 January 2018

1 reference

In vitro activity of caspofungin and voriconazole against uncommon Candida spp.

21 January 2018

1 reference

In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program

21 January 2018

1 reference

International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003).

21 January 2018

1 reference

Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).

21 January 2018

1 reference

Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing

21 January 2018

1 reference

In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole

21 January 2018

1 reference

Clinical isolates of Aspergillus species remain fully susceptible to voriconazole in the post-voriconazole era.

21 January 2018

1 reference

In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum

21 January 2018

1 reference

In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi

21 January 2018

1 reference

In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi

21 January 2018

1 reference

In vitro activity of amphotericin B, itraconazole, voriconazole, posaconazole, caspofungin and terbinafine against Scytalidium dimidiatum and Scytalidium hyalinum clinical isolates

21 January 2018

1 reference

Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method

21 January 2018

1 reference

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts

21 January 2018

1 reference

Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.

21 January 2018

1 reference

Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.

21 January 2018

1 reference

Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.

21 January 2018

1 reference

In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans

21 January 2018

1 reference

In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing

21 January 2018

1 reference

In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents

21 January 2018

1 reference

Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers

21 January 2018

1 reference

Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B.

21 January 2018

1 reference

In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes

21 January 2018

1 reference

Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy

21 January 2018

1 reference

Determination of in vitro susceptibility of ocular Fusarium spp. isolates from keratitis cases and comparison of Clinical and Laboratory Standards Institute M38-A2 and E test methods

21 January 2018

1 reference

Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections.

21 January 2018

1 reference

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

21 January 2018

1 reference

In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing

21 January 2018

1 reference

In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi

21 January 2018

1 reference

Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus

21 January 2018

1 reference

Antifungal susceptibility profiles of Coccidioides immitis and Coccidioides posadasii from endemic and non-endemic areas

21 January 2018

1 reference

In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.

21 January 2018

1 reference

In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba

21 January 2018

1 reference

Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans

21 January 2018

1 reference

In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.

21 January 2018

1 reference

In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing

21 January 2018

1 reference

In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi

21 January 2018

1 reference

Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review

21 January 2018

1 reference

In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans

21 January 2018

1 reference

In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents

21 January 2018

1 reference

In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole

21 January 2018

1 reference

In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B

21 January 2018

1 reference

In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates

21 January 2018

1 reference

In vitro antifungal susceptibility of Cryptococcus gattii

21 January 2018

1 reference

In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates

21 January 2018

1 reference

Antifungal susceptibilities of the species of the Pseudallescheria boydii complex

21 January 2018

1 reference

Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods.

21 January 2018

1 reference

Susceptibility testing and molecular classification of Paecilomyces spp.

21 January 2018

1 reference

New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones

21 January 2018

1 reference

In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp

21 January 2018

1 reference

In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.

21 January 2018

1 reference

Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole

21 January 2018

1 reference

In vitro interactions of licensed and novel antifungal drugs against Fusarium spp.

21 January 2018

1 reference

In vitro activities of four novel triazoles against Scedosporium spp

21 January 2018

1 reference

In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds.

21 January 2018

1 reference

In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi

21 January 2018

1 reference

Antifungal drug resistance: limited data, dramatic impact?

21 January 2018

1 reference

Mode of action and resistance to azole antifungals associated with the formation of 14 alpha-methylergosta-8,24(28)-dien-3 beta,6 alpha-diol.

21 January 2018

1 reference

Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences

21 January 2018

1 reference

Antifungal resistance in pathogenic fungi

21 January 2018

1 reference

Multiple resistance mechanisms to azole antifungals in yeast clinical isolates.

21 January 2018

1 reference

Efflux-mediated antifungal drug resistance.

21 January 2018

1 reference

Regulated overexpression of CDR1 in Candida albicans confers multidrug resistance.

21 January 2018

1 reference

Establishing surrogate markers for fluconazole resistance in Candida albicans

21 January 2018

1 reference

Genome-wide expression profile analysis reveals coordinately regulated genes associated with stepwise acquisition of azole resistance in Candida albicans clinical isolates

21 January 2018

1 reference

Genome-wide expression and location analyses of the Candida albicans Tac1p regulon.

21 January 2018

1 reference

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

21 January 2018

1 reference

Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance

21 January 2018

1 reference

Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp

21 January 2018

1 reference

Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole

21 January 2018

1 reference

Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans

21 January 2018

1 reference

Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata.

21 January 2018

1 reference

Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors

21 January 2018

1 reference

Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei

21 January 2018

1 reference

Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005

21 January 2018

1 reference

Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact

21 January 2018

1 reference

Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole.

21 January 2018

1 reference

Targeted gene disruption of the 14-alpha sterol demethylase (cyp51A) in Aspergillus fumigatus and its role in azole drug susceptibility.

21 January 2018

1 reference

Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs

21 January 2018

1 reference

A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.

21 January 2018

1 reference

The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy

21 January 2018

1 reference

Microbial natural products as a source of antifungals

21 January 2018

1 reference

Anidulafungin: a new echinocandin with a novel profile

21 January 2018

1 reference

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

21 January 2018

1 reference

Echinocandin antifungal drugs

21 January 2018

1 reference

Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility

21 January 2018

1 reference

Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1

21 January 2018

1 reference

Analysis of beta-1,3-glucan assembly in Saccharomyces cerevisiae using a synthetic interaction network and altered sensitivity to caspofungin

21 January 2018

1 reference

Mutations in Fks1p affect the cell wall content of beta-1,3- and beta-1,6-glucan in Saccharomyces cerevisiae.

21 January 2018

1 reference

1,3-beta-Glucan synthase: a useful target for antifungal drugs

21 January 2018

1 reference

Echinocandins: role in antifungal therapy, 2005.

21 January 2018

1 reference

Comparison of echinocandin antifungals

21 January 2018

1 reference

The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans

21 January 2018

1 reference

In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole

21 January 2018

1 reference

Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.

21 January 2018

1 reference

In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

21 January 2018

1 reference

Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.

21 January 2018

1 reference

In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance

21 January 2018

1 reference

Serum differentially alters the antifungal properties of echinocandin drugs

21 January 2018

1 reference

Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006

21 January 2018

1 reference

In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.

21 January 2018

1 reference

Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001).

21 January 2018

1 reference

Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit

21 January 2018

1 reference

Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.

21 January 2018

1 reference

Initial results from a longitudinal international surveillance programme for anidulafungin (2003).

21 January 2018

1 reference

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991).

21 January 2018

1 reference

Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species

21 January 2018

1 reference

Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia

21 January 2018

1 reference

In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates

21 January 2018

1 reference

In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.

21 January 2018

1 reference

Fungal ß(1,3)-D-glucan synthesis

21 January 2018

1 reference

Resistance to echinocandin-class antifungal drugs

21 January 2018

1 reference

Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates

21 January 2018

1 reference

Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase

21 January 2018

1 reference

Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis

21 January 2018

1 reference

Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment

21 January 2018

1 reference

Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin.

21 January 2018

1 reference

Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing

21 January 2018

1 reference

Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy

21 January 2018

1 reference

The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin.

21 January 2018

1 reference

Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility

21 January 2018

1 reference

Caspofungin activity against clinical isolates of fluconazole-resistant Candida

21 January 2018

1 reference

Caspofungin uptake is mediated by a high-affinity transporter in Candida albicans

21 January 2018

1 reference

Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae

21 January 2018

1 reference

Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin

21 January 2018

1 reference

A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus

21 January 2018

1 reference

Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins.

21 January 2018

1 reference

In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi

21 January 2018

1 reference

Fluconazole resistance mechanisms inCandida krusei: The contribution of efflux-pumps

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERI.09.67

1 reference

21 August 2017

1 reference

PubMed ID

19803707